Rethinking universal anti-fibrinolysis: a randomized controlled trial on divergent fibrinolytic phenotypes in total knee arthroplasty

Jiacheng Liu; Tao Zhang; Xuefeng Luo; Dehua Wang; Runxing Kang; Xiangru Shen; Yinsong Sun; Mingfei Dong; Ke Li; Wei Huang; Yiting Lei

doi:10.1093/burnst/tkaf004

Burns & Trauma ›› 2025, Vol. 13 ›› Issue (1) :tkaf004 DOI: 10.1093/burnst/tkaf004

Rapid Communications

research-article

Rethinking universal anti-fibrinolysis: a randomized controlled trial on divergent fibrinolytic phenotypes in total knee arthroplasty

Jiacheng Liu ¹^,²^,³^,^‡
, Tao Zhang ⁴^,^‡
, Xuefeng Luo ¹^,²^,³^,^‡
, Dehua Wang ¹^,²^,³
, Runxing Kang ¹^,²^,³
, Xiangru Shen ¹^,²^,³
, Yinsong Sun ¹^,²^,³
, Mingfei Dong ¹^,²^,³
, Ke Li ¹^,²^,³^,^*
, Wei Huang ¹^,²^,³^,^*
, Yiting Lei ¹^,²^,³^,⁵^,^*

Author information +

History +

PDF (611KB)

Cite this article

Download citation ▾

Jiacheng Liu, Tao Zhang, Xuefeng Luo, Dehua Wang, Runxing Kang, Xiangru Shen, Yinsong Sun, Mingfei Dong, Ke Li, Wei Huang, Yiting Lei. Rethinking universal anti-fibrinolysis: a randomized controlled trial on divergent fibrinolytic phenotypes in total knee arthroplasty. Burns & Trauma, 2025, 13 (1) : tkaf004 DOI:10.1093/burnst/tkaf004

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Li ZJ, Zhao MW, Zeng L. Additional dose of intravenous Tranexamic acid after primary Total knee arthroplasty further reduces hidden blood loss. Chin Med J 2018; 131: 638-42. https://doi.org/10.4103/0366-6999.226884.

[2]

Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, et al. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American association of hip and knee surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of orthopaedic surgeons, hip society, and knee society. Reg Anesth Pain Med 2019; 44: 7-11. https://doi.org/10.1136/rapm-2018-000024.

[3]	Xu J, Zhang Y, Nie G. Intelligent antithrombotic nanomedicines: progress, opportunities, and challenges. VIEW 2021; 2: 20200145. https://doi.org/10.1002/VIW.20200145.

[4]

Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a Multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 2016; 222: 347-55. https://doi.org/10.1016/j.jamcollsurg.2016.01.006.

[5]	Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, et al. Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015; 78: S65-9. https://doi.org/10.1097/TA.0000000000000634.

[6]	Liu J, Lei Y, Liao J, Liang X, Hu N, Huang W. Pre-Emptive Antifibrinolysis: its role and efficacy in hip fracture patients undergoing Total hip arthroplasty. J Arthroplast 2022; 37: 755-62. https://doi.org/10.1016/j.arth.2021.12.034.

[7]	Lei Y, Xie J, Huang Q, Pei F. Is there a maximal effect of tranexamic acid in patients undergoing total knee arthroplasty? A randomized controlled trial. MedComm 2020; 1: 219-27. https://doi.org/10.1002/mco2.23.

[8]	Medcalf RL, Keragala CB, Draxler DF.Fibrinolysis and the immune response in trauma. Semin Thromb Hemost 2020; 46: 176-82. https://doi.org/10.1055/s-0040-1702170.

[9]	Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers 2021; 7: 30. https://doi.org/10.1038/s41572-021-00264-3.

[10]	Xu Y, Yu G, Nie R, Wu Z. Microfluidic systems toward blood hemostasis monitoring and thrombosis diagnosis: from design principles to micro/nano fabrication technologies. VIEW 2022; 3: 20200183. https://doi.org/10.1002/VIW.20200183.